CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(04): 237-238
Emerging role of circulating tumor cells in cancer management
Michal Mego
Department of Medical Oncology, Translational Research Unit, Comenius University, Faculty of Medicine and National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic
› Author Affiliations
References
1 Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al . Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
2 Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel) 2014;6:684-707.
3 Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al . HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004;101:9393-8.
4 Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One 2013;8:e75038.
5 Turner NH, Di Leo A. HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact. Cancer Treat Rev 2013;39:947-57.
6 Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010;15:1164-8.
7 Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, et al . Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer 2012;130:808-16.
8 Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, et al . Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer 2011;129:417-23.
9 Friedlander TW, Fong L. The end of the beginning: Circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol 2014;32:1104-6.
10 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371: 1028-38.
